On 28 July 2015, orphan designation (EU/3/15/1529) was granted by the European Commission to QRC Consultants Ltd., United Kingdom, for glycyl-L-2-methylprolyl-L-glutamic acid for the treatment of fragile X syndrome.
The sponsorship was transferred to DLRC Pharma Services Ltd, Ireland, in February 2019.
|Disease / condition||
Treatment of fragile X syndrome
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;